Mozhgan Lotfi

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis”.

Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis

Nature Communications(2024)10.1038/s41467-024-52005-1

N/A

0.823DataRank · unranked

29 citations

Yapei Zhang, Manisha Kumari, Mozhgan Lotfi, Tom Alsaigh, Lingfeng Luo +21 more

Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis

Nature Nanotechnology(2020)10.1038/s41565-019-0619-3

N/A

0DataRank · unranked

284 citations

Niloufar Hosseini-Nassab, Kai-Uwe Jarr, Jianqin Ye, Xingjun Zhu, Robert Wirka +13 more

The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis

Nature Cardiovascular Research(2022)10.1038/s44161-022-00023-x

N/A

0DataRank · unranked

56 citations

Jianqin Ye, Yoko Kojima, Zhongde Ye, Hua Gao, Sofie Schmid +10 more